Stabilizing Off-pathway Oligomers by Polyphenol Nanoassemblies for IAPP Aggregation Inhibition
- PMID: 26763863
- PMCID: PMC4725907
- DOI: 10.1038/srep19463
Stabilizing Off-pathway Oligomers by Polyphenol Nanoassemblies for IAPP Aggregation Inhibition
Abstract
Experimental studies have shown that many naturally occurring polyphenols have inhibitory effect on the aggregation of several proteins. Here, we use discrete molecular dynamics (DMD) simulations and high-throughput dynamic light scattering (DLS) experiments to study the anti-aggregation effects of two polyphenols, curcumin and resveratrol, on the aggregation of islet amyloid polypeptide (IAPP or amylin). Our DMD simulations suggest that the aggregation inhibition is caused by stabilization of small molecular weight IAPP off-pathway oligomers by the polyphenols. Our analysis indicates that IAPP-polyphenol hydrogen bonds and π-π stacking combined with hydrophobic interactions are responsible for the stabilization of oligomers. The presence of small oligomers is confirmed with DLS measurements in which nanometer-sized oligomers are found to be stable for up to 7.5 hours, the time frame within which IAPP aggregates in the absence of polyphenols. Our study offers a general anti-aggregation mechanism for polyphenols, and further provides a computational framework for the future design of anti-amyloid aggregation therapeutics.
Figures






Similar articles
-
Atomistic mechanism of polyphenol amyloid aggregation inhibitors: molecular dynamics study of Curcumin, Exifone, and Myricetin interaction with the segment of tau peptide oligomer.J Biomol Struct Dyn. 2015;33(7):1399-411. doi: 10.1080/07391102.2014.951689. Epub 2014 Sep 9. J Biomol Struct Dyn. 2015. PMID: 25093402
-
Structural basis for the inhibition of truncated islet amyloid polypeptide aggregation by Cu(II): insights into the bioinorganic chemistry of type II diabetes.Inorg Chem. 2015 Apr 20;54(8):3788-96. doi: 10.1021/ic502945k. Epub 2015 Mar 31. Inorg Chem. 2015. PMID: 25826050
-
β-Hairpin of Islet Amyloid Polypeptide Bound to an Aggregation Inhibitor.Sci Rep. 2016 Sep 19;6:33474. doi: 10.1038/srep33474. Sci Rep. 2016. PMID: 27641459 Free PMC article.
-
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus.Clin Interv Aging. 2015 Nov 19;10:1873-9. doi: 10.2147/CIA.S95297. eCollection 2015. Clin Interv Aging. 2015. PMID: 26604727 Free PMC article. Review.
-
β-sheet interfering molecules acting against β-amyloid aggregation and fibrillogenesis.Bioorg Med Chem. 2015 Apr 15;23(8):1671-83. doi: 10.1016/j.bmc.2015.02.041. Epub 2015 Feb 28. Bioorg Med Chem. 2015. PMID: 25769517 Review.
Cited by
-
Vitamin k3 inhibits protein aggregation: Implication in the treatment of amyloid diseases.Sci Rep. 2016 May 27;6:26759. doi: 10.1038/srep26759. Sci Rep. 2016. PMID: 27230476 Free PMC article.
-
It's ok to be outnumbered - sub-stoichiometric modulation of homomeric protein complexes.RSC Med Chem. 2022 Oct 27;14(1):22-46. doi: 10.1039/d2md00212d. eCollection 2023 Jan 25. RSC Med Chem. 2022. PMID: 36760737 Free PMC article. Review.
-
Zinc-Epigallocatechin-3-gallate Network-Coated Nanocomposites against the Pathogenesis of Amyloid-Beta.ACS Appl Mater Interfaces. 2023 Feb 15;15(6):7777-7792. doi: 10.1021/acsami.2c20334. Epub 2023 Feb 1. ACS Appl Mater Interfaces. 2023. PMID: 36724494 Free PMC article.
-
Polyphenols with Anti-Amyloid β Aggregation Show Potential Risk of Toxicity Via Pro-Oxidant Properties.Int J Mol Sci. 2020 May 18;21(10):3561. doi: 10.3390/ijms21103561. Int J Mol Sci. 2020. PMID: 32443552 Free PMC article. Review.
-
Pancreatic β-Cell Membrane Fluidity and Toxicity Induced by Human Islet Amyloid Polypeptide Species.Sci Rep. 2016 Feb 16;6:21274. doi: 10.1038/srep21274. Sci Rep. 2016. PMID: 26880502 Free PMC article.
References
-
- Glabe C. G. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 27, 570–575 (2006). - PubMed
-
- Kayed R. et al.. Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in Vitro 1. J. Mol. Biol. 287, 781–796 (1999). - PubMed
-
- Macdonald I. A. Amylin and the gastrointestinal tract. Diabet. Med. J. Br. Diabet. Assoc. 14 Suppl 2, S24–28 (1997). - PubMed
-
- Young D. A., Deems R. O., Deacon R. W., McIntosh R. H. & Foley J. E. Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am. J. Physiol.-Endocrinol. Metab. 259, E457 (1990). - PubMed
-
- Cohen F. E. & Kelly J. W. Therapeutic approaches to protein-misfolding diseases. Nature 426, 905–909 (2003). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous